Navis Capital has successfully sold Frecan, achieving returns that exceed targeted profitability and validating its investment thesis in value generation within the MedTech sector.
Target Information
Navis Capital has successfully sold Frecan, achieving returns that significantly exceed the vehicle's targeted profitability. This success validates their investment thesis regarding value generation through effective management of portfolio companies. Frecan has demonstrated strong performance and aligns well with the firm's strategic goals.
Frecan, recognized for its innovation and operational excellence, has been a key player in the market, contributing to Navis Capital's overall value creation. The sale reflects the growing demand for high-quality investments in the sector and highlights Frecan's effective leadership and growth strategy.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Country
The current landscape for the MedTech industry in Spain shows promising growth fueled by technological advancements and increasing healthcare investments. With a vib
Similar Deals
Asabys, Buenavista, GoHub Ventures, UI Investissement, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, individual investors → Quibim
2025
Asabys Partners and Buenavista Equity Partners → Quibim
2025
Sherpa Capital
invested in
Logística Carosan
in 2024
in a Series A deal